ZVRA

In the past six months, ZVRA's stock has trended upwards by 10.16%, with its 52-week range between $8.01 and $15.04. As of early October 2026, the stock experienced a losing streak of three trading days. Market sentiment has shown some concern regarding higher interest rates impacting biotech stocks, though Zevra is noted for not needing immediate cash, thus mitigating some financing concerns. In July 2026, several law firms issued investor alerts and initiated investigations into Zevra Therapeutics, Inc.